Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.

IBM unveiled a $150 billion plan to invest in the U.S., adding to a series of commitments by big corporations. Here's a rundown of some of the multibillion-dollar pledges made since President Trump to ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

We recently published a list of 10 Best Stocks That Will Always Grow. In this article, we are going to take a look at where ...

Eli Lilly stock has been a big-time winner ... retaliatory tariffs from other countries could also weigh on Lilly's business; the company could start to see diminished brand equity in ...

Eli Lilly said in February that it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company ...

But what matters more than Lilly's accomplishments in the past is what the company could do in the future. Where will Eli Lilly be in five years? Where to invest $1,000 right now? Our analyst team ...

From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...

Eli Lilly's new experimental pill called orforglipron, helped patients shed weight and control blood sugar as well as blockbuster drug Ozempic in a trial of diabetes patients, and the company ...